Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism

被引:43
作者
Cipolla, MJ
Nicoloff, A
Rebello, T
Amato, A
Porter, JM
机构
[1] Oregon Hlth Sci Univ, Div Vasc Surg, Dept Surg, Portland, OR 97201 USA
[2] Sigma Tau Pharmaceut, Gaithersburg, MD USA
关键词
D O I
10.1016/S0741-5214(99)70251-X
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: The vasoactive effects of propionyl-1-carnitine (PLC) on human arteries, including endothelial and smooth muscle cell influences, were studied. Methods: Small (less than 200 mu m) subcutaneous fat arteries (n = 19), obtained from human patients undergoing vascular surgery, were dissected and mounted in an arterio-graph system that allowed measurement of lumen diameter and control of transmural pressure. To investigate the role of the endothelium, arteries were compared intact, intact and in the presence of either 0.3 mmol/L nitro-1-arginine (an inhibitor of nitric oxide synthesis) or 10 mu mol/L indomethacin (an inhibitor of prostaglandin synthesis), or denuded of endothelium. After a 1-hour equilibration at a pressure of 50 mm Hg, arteries were precontracted 50% with an intermediate concentration of norepinephrine, and clinically relevant concentrations of PLC (0.1 to 100 mu mol/L) were cumulatively added to the bath while the lumen diameter was continually measured. Results: Intact arteries dose-dependently dilated to PLC, with the half maximal dilation occurring at 2.9 +/- 1.2 mu mol/L, increasing diameter 91% +/- 5% at 100 mu mol/L. In contrast, PLC had significantly less effect on deendothelialized arteries, increasing diameter only 24% +/- 11% at 100 mu mol/L (P < .01 vs. intact). This indicates the endothelial dependency of this compound. Blockade of nitric oxide did not inhibit this vasodilation, with the half-maximal response occurring at 8.6 +/- 7 mu mol/L, increasing diameter 85% +/- 8% at 100 mu mol/L (P > .05 vs, intact). However, this vasodilation was significantly diminished in the presence of indomethacin, which dilated arteries only 53% +/- 18% at 100 mu mol/L (P < .01 vs, intact; P > .05 vs. denuded). Conclusion: PLC is an endothelium-dependent vasodilator, the mechanism of which is partially mediated by prostaglandin synthesis, not nitric oxide. The beneficial effects of this compound may, in part, be related to vasodilation and enhanced blood flow.
引用
收藏
页码:1097 / 1103
页数:7
相关论文
共 25 条
[1]  
BERTELLI A, 1993, DRUG EXP CLIN RES, V19, P75
[2]   CARNITINE DELAYS RAT SKELETAL-MUSCLE FATIGUE IN-VITRO [J].
BRASS, EP ;
SCARROW, AM ;
RUFF, LJ ;
MASTERSON, KA ;
VANLUNTEREN, E .
JOURNAL OF APPLIED PHYSIOLOGY, 1993, 75 (04) :1595-1600
[3]   INCREASES IN WALKING DISTANCE IN PATIENTS WITH PERIPHERAL VASCULAR-DISEASE TREATED WITH L-CARNITINE - A DOUBLE-BLIND, CROSSOVER STUDY [J].
BREVETTI, G ;
CHIARIELLO, M ;
FERULANO, G ;
POLICICCHIO, A ;
NEVOLA, E ;
ROSSINI, A ;
ATTISANO, T ;
AMBROSIO, G ;
SILIPRANDI, N ;
ANGELINI, C .
CIRCULATION, 1988, 77 (04) :767-773
[4]   PROPIONYL-L-CARNITINE IN INTERMITTENT CLAUDICATION - DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTICENTER STUDY [J].
BREVETTI, G ;
PERNA, S ;
SABBA, C ;
MARTONE, VD ;
CONDORELLI, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (06) :1411-1416
[5]   MUSCLE CARNITINE DEFICIENCY IN PATIENTS WITH SEVERE PERIPHERAL VASCULAR-DISEASE [J].
BREVETTI, G ;
ANGELINI, C ;
ROSA, M ;
CARROZZO, R ;
PERNA, S ;
CORSI, M ;
MATARAZZO, A ;
MARCIALIS, A .
CIRCULATION, 1991, 84 (04) :1490-1495
[6]   SUPERIORITY OF L-PROPIONYLCARNITINE VS L-CARNITINE IN IMPROVING WALKING CAPACITY IN PATIENTS WITH PERIPHERAL VASCULAR-DISEASE - AN ACUTE, INTRAVENOUS, DOUBLE-BLIND, CROSS-OVER STUDY [J].
BREVETTI, G ;
PERNA, S ;
SABBA, C ;
ROSSINI, A ;
DIUCCIO, VS ;
BERARDI, E ;
GODI, L .
EUROPEAN HEART JOURNAL, 1992, 13 (02) :251-255
[7]  
CEVESE A, 1995, CARDIOSCIENCE, V6, P59
[8]   ARACHIDONIC-ACID SYNTHESIS STUDIES IN ISOLATED LIVER-CELLS - EFFECTS OF (-)-CARNITINE AND OF (+)-DECANOYLCARNITINE [J].
CHRISTOPHERSEN, BO ;
NORSETH, J .
FEBS LETTERS, 1981, 133 (02) :201-204
[9]   Endothelial function and adrenergic reactivity in human type-II diabetic resistance arteries [J].
Cipolla, MJ ;
Harker, CT ;
Porter, JM .
JOURNAL OF VASCULAR SURGERY, 1996, 23 (05) :940-949
[10]   VASODILATOR ACTION OF THE ISOPROPYL ESTER OF PALMITOYL CARNITINE IN THE RAT CORONARY CIRCULATION AND MESENTERIC VASCULAR BED [J].
CRIDDLE, DN ;
RADNIKNAM, M ;
DEWAR, GH ;
WOODWARD, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 255 (1-3) :223-228